Gastrointestinal Cancer clinical trials at University of California Health
13 in progress, 10 open to eligible people
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
open to eligible people ages 18 years and up
This is a multicenter, open-label, prospective Phase 1/2a study to assess safety and tolerability, establish dosimetry and to identify an optimal imaging dose (radioactivity and mass dose) and imaging time window of 64Cu-LNTH-1363S (64Cu…
at UC Irvine
MK-2870 Alone or With Chemotherapy to Treat Gastrointestinal Cancers (MK-9999-02A)
open to eligible people ages 18 years and up
Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with chemotherapy can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the body), or…
at UCLA
RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer
open to eligible people ages 18 years and up
This is a Phase 1 study currently evaluating PO administered ompenaclid in combination with FOLFIRI and bevacizumab in patients with advanced (i.e., locally advanced and unresectable, or metastatic) previously treated colorectal adenocarcinoma. The…
at UCLA
Ketamine-assisted Therapy for Advanced GI Cancer
open to eligible people ages 18 years and up
This clinical trial evaluates whether it is possible to use a single dose of ketamine in combination with talk therapy to treat moderate to severe demoralization in patients with stage 3 or 4 gastrointestinal (GI) cancers who take opioids for…
at UCSF
PhI Pilot Study Pafolacianine Inject for Intraoperative Imaging on Outcomes of GI Cancer Peritoneal Carcinomatosis
open to eligible people ages 18 years and up
This is a pilot, single-arm, open label study to evaluate the ability of CYTALUX™ (pafolacianine) to help identify cancerous lesions in subjects with gastrointestinal cancers and peritoneal carcinomatosis during cytoreductive surgery.
at UC Irvine
Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers
open to eligible people ages 18 years and up
This phase II trial studies how well radiation therapy works for the treatment of gastrointestinal cancer that are spreading to other places in the body (metastatic). Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors.…
at UCSF
BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
open to eligible people ages 18 years and up
This clinical trial is evaluating a drug called BT5528 alone and in combination with nivolumab in participants with advanced solid tumors historically known for expression of EphA2. The main goals of this study are to: - Find the recommended dose(s) …
at UC Irvine UCSD
[18F]FAPI-74 PET in Patients With Gastrointestinal Cancers
open to eligible people ages 18 years and up
Prospective, multi-center, open label, non-randomized clinical trial to assess efficacy of [18F]FAPI-74 to detect FAP expressing cells in patients diagnosed with gastrointestinal cancers, including hepatocellular carcinoma, cholangiocarcinoma,…
at UCLA
RAS(ON) Inhibitors in Patients with Gastrointestinal Solid Tumors
open to eligible people ages 18 years and up
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current subprotocols…
at UCLA
Fatigue and Molecular Mechanisms in Cancer Patients Receiving CCRT
open to eligible people ages 18 years and up
Cancer-related fatigue (CRF) is a significant problem for cancer patients. This prospective, basic science, observational study will evaluate for changes in CRF associated with molecular characteristics prior to, during, and at the completion of…
at UCSF
Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer
Sorry, in progress, not accepting new patients
This is a Global Study of Neoadjuvant-Adjuvant Durvalumab or Placebo and FLOT Chemotherapy Followed by Adjuvant Durvalumab or Placebo in Patients with Resectable Gastric and Gastroesophageal Cancer (GC/GEJC) (MATTERHORN).
at UCLA
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Sorry, in progress, not accepting new patients
This randomized phase II trial studies how well pazopanib hydrochloride works in treating patients with carcinoid tumors that are growing, spreading, or getting worse. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of…
at UCSF
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Sorry, in progress, not accepting new patients
This phase III trial studies cabozantinib to see how well it works compared with placebo in treating patients with neuroendocrine or carcinoid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of …
at UC Davis UCSF
Our lead scientists for Gastrointestinal Cancer research studies include Maheswari Senthil, MD Mary Feng Shyam Srinivas, MD, PhD Mark Girgis, M.D. Misako Nagasaka, MD Emily Bergsland Zev Wainberg Brian T Anderson, MD Sue Yom, MD Lee Rosen.
Last updated: